Barclays Raises Valeant Pharmaceuticals' Price Target

By: via Benzinga
Barclays raised its price target on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) from $149 to $179 Friday and maintained a Buy ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.